Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

March

29

Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases

Collaboration with Emory University will utilize the AVISE® testing portfolio SAN DIEGO, March 29, 2021 (GLOBE...

25

Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Gross proceeds approximately $69.1 million before underwriting discounts and commissions and other offering expenses...

22

Exagen Inc. Announces Pricing of Public Offering of Common Stock

Offering 3.7 million shares of common stock at $16.25/share SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE)...

16

Exagen Inc. Reports Fourth Quarter and Full Year 2020 Results

Quarterly Records: Revenue, Gross Margin, AVISE® CTD Volumes, and Adopters SAN DIEGO, March 16, 2021 (GLOBE...

21

Exagen Inc. Partners with Boston’s Tufts Medical Center to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the...

16

Exagen and GSK Partner for Fourth Straight Year

Continued collaboration drives greater awareness of challenges facing lupus diagnosis and management SAN DIEGO, Nov....

10

Exagen Inc. Reports Third Quarter 2020 Results

Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing...

12

New Data Demonstrates Economic Benefit of Exagen’s AVISE® Lupus Test for Payors

Findings support the clinical need for an improved SLE diagnostic test SAN DIEGO, Oct. 12,...

29

Exagen Inc. Announces Agreement with Provider Network of America

Expanding Access for AVISE® Tests to 8 Million Members SAN DIEGO, Sept. 29, 2020 (GLOBE NEWSWIRE)...

3

Exagen Inc. Announces Clinical Trial Conducted at Major Academic Center in Distinguishing Type 1 and Type 2 Lupus

Duke Lupus Clinic is focused on diagnosing, treating, and providing expert care to patients living...

11

Exagen Inc. Reports First Quarter 2020 Results

AVISE® Testing Volumes Increase with Retention Rate of 99% SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE)...

9

Exagen Inc. Partners with Three California Medical Groups to Offer AVISE Testing as Covered In-Network Benefit for Their Patients

AVISE testing can facilitate improved care through the differential diagnosis, prognosis, management, and therapeutic...

Recent developments

News

March

29

Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases

March

25

Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

March

22

Exagen Inc. Announces Pricing of Public Offering of Common Stock

March

16

Exagen Inc. Reports Fourth Quarter and Full Year 2020 Results

January

21

Exagen Inc. Partners with Boston’s Tufts Medical Center to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

November

16

Exagen and GSK Partner for Fourth Straight Year

November

10

Exagen Inc. Reports Third Quarter 2020 Results

October

12

New Data Demonstrates Economic Benefit of Exagen’s AVISE® Lupus Test for Payors

September

29

Exagen Inc. Announces Agreement with Provider Network of America

June

3

Exagen Inc. Announces Clinical Trial Conducted at Major Academic Center in Distinguishing Type 1 and Type 2 Lupus

May

11

Exagen Inc. Reports First Quarter 2020 Results

March

9

Exagen Inc. Partners with Three California Medical Groups to Offer AVISE Testing as Covered In-Network Benefit for Their Patients